Pharmaceuticals

Johnson & Johnson Enters into Agreement to Acquire Yellow Jersey Therapeutics for $1.25 Billion in All Cash Transaction

bexib
By bexib 0 Min Read

The acquisition of Yellow Jersey Therapeutics includes access to NM26, a potential treatment for atopic dermatitis.

You Might Also Like

APL and CurifyLabs Partner to Support Patients with 3D Printed Medical Technology

Phase 2 PREDICT-ILD Imaging Study in Interstitial Lung Disease Begins

New ways to determine drug value with health equity in mind

Melissa Krebs Shares Gersana’s Vision for Innovative Wound Care Solutions

Zongertinib demonstrates high objective response rates in previously treated advanced non-small cell lung cancer

Share This Article
Previous Article Weekly initial unemployment claims fall to 222,000
Next Article What is TapSwap? Discover this play and earn game – Investorempires.com
Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

From Porsche to Purpose: A CMO’s Journey
Retail & E-commerce
Upskilling: An interview with Steph Piper
Manufacturing
Young Kiwis toast change: hazardous drinking falls by 13% in five years
Hospitality & Tourism
Clearview FCU saves 6,000 labor hours through RPA
Banking